Skip to main content

Table 1 Patient and disease baseline characteristics for premenopausal patients in the MONARCH 2 trial

From: Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial

  Abemaciclib + fulvestrant
N = 72
Placebo + fulvestrant
N = 42
Median age (range) 46 (32–57) 47 (32–66)
Race, n (%)
 Asian 51 (70.8) 24 (57.1)
 Caucasian 14 (19.4) 16 (38.1)
 Other 7 (9.7) 2 (4.8)
Most recent ET, n (%)a
 Neoadjuvant or adjuvant 44 (61.1) 21 (50.0)
 Metastatic 26 (36.1) 20 (47.6)
Number of lines of ET, n (%)
 1 60 (83.3) 30 (71.4)
 2 10 (13.9) 11 (26.2)
Prior AI, n (%)
 Yes 10 (13.9) 12 (28.6)
 No 62 (86.1) 30 (71.4)
Sensitivity to ET, n (%)a
 Primary resistanceb 28 (38.9) 15 (35.7)
 Secondary resistancec 42 (58.3) 26 (61.9)
Progesterone-receptor status, n (%)
 Positive 54 (75.0) 38 (90.5)
 Negative 18 (25.0) 4 (9.5)
Metastatic site, n (%)
 Visceral 43 (59.7) 17 (40.5)
 Bone only 19 (26.4) 15 (35.7)
 Other 10 (13.9) 10 (23.8)
Measurable disease, n (%)
 Yes 51 (70.8) 28 (66.7)
 No 21 (29.2) 14 (33.3)
ECOG performance status
 0 54 (75.0) 36 (85.7)
 1 18 (25.0) 6 (14.3)
  1. AI, aromatase inhibitor; ECOG, Eastern Cooperative Oncology Group; ET, endocrine therapy
  2. aTwo patients in the abemaciclib arm and one patient in the placebo arm received no prior ET; bPatients whose disease relapsed ≤ 2 years while receiving (neo) adjuvant ET or progressed ≤ 6 months of receiving ET for ABC; cPatients receiving prior ET who do not meet the definition of primary resistance were considered to have secondary resistance